FK778 Attenuates Cytomegalovirus-Enhanced Vein Graft Intimal Hyperplasia in a Rat Model | Zendy

Geoffrey Kloppenburg | Zendy; Rick de Graaf | Zendy; Gert Grauls | Zendy; Cathrien A. Bruggeman | Zendy; Johannes P. van Hooff | Zendy; Frank Stassen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

FK778 Attenuates Cytomegalovirus-Enhanced Vein Graft Intimal Hyperplasia in a Rat Model

Author(s) -

Geoffrey Kloppenburg,

Rick de Graaf,

Gert Grauls,

Cathrien A. Bruggeman,

Johannes P. van Hooff,

Frank Stassen

Publication year - 2009

Publication title -

intervirology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.641

H-Index - 61

eISSN - 1423-0100

pISSN - 0300-5526

DOI - 10.1159/000225194

Subject(s) - intimal hyperplasia , medicine , hyperplasia , neointimal hyperplasia , urology , vein , cytomegalovirus , artery , surgery , smooth muscle , immunology , restenosis , herpesviridae , virus , stent , viral disease

Venous grafts are commonly used to treat drug-resistant coronary artery disease, although long-term functionality is limited because of proliferation and migration of smooth muscle cells (SMC). As proliferating SMC are particularly susceptible for the stimulating effects of cytomegalovirus (CMV), we hypothesized that CMV infection may enhance cell proliferation and graft failure. Furthermore, we evaluated the potential of FK778 to prevent intimal hyperplasia. Apart from its antiviral properties, FK778 is a new immunosuppressive agent which may also affect SMC proliferation, making it an interesting drug to prevent (CMV-enhanced) venous graft intimal hyperplasia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research